Thyroid Eye Disease

ATLANTA — In this video exclusive, Terry Smith, MD, discusses results of an analysis of clinical trial data on blood glucose effects associated with teprotumumab therapy for thyroid eye disease.

IV methylprednisolone was linked to a small change in proptosis from baseline compared with placebo in patients with thyroid eye disease, while teprotumumab may improve proptosis and diplopia vs. IV methylprednisolone.

Adults with thyroid eye disease and diabetes have a higher prevalence of diplopia, strabismus and sight-threatening disease compared with those without diabetes, according to study findings published in Endocrine Practice.

AUSTIN, Texas — In this Healio Video Perspective from the North American Neuro-Ophthalmology Society meeting, Prem Subramanian, MD, PhD, discusses the sustained efficacy of teprotumumab in patients with thyroid eye disease.

The Healio and Endocrine Today editors have compiled the most popular thyroid news stories from 2021.

Endocrine Today editors have compiled the top cover stories published in 2021.

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Raymond Douglas, MD, PhD, discusses results of a clinical trial examining adherence to teprotumumab and reasons for nonadherence in patients with thyroid eye disease.

NEW ORLEANS — Teprotumumab may offer comparable proptosis efficacy in patients with thyroid eye disease with low levels of inflammation as seen in patients with higher levels of inflammatory activity, according to a study.

Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker.

Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers.